Travere Therapeutics, Inc. TVTX Return on equity

Return on equity at other companies

Vertex PharmaceuticalsVRTX

23.5%—

Jade BiosciencesJBIO

-132.5%+120pp

Vera TherapeuticsVERA

-71.3%+296pp

Eton Pharmaceuticals, Inc.ETON

-34.2%+0.9pp

Viridian Therapeutics, Inc.VRDN

-65.7%-0.1pp

ANI PharmaceuticalsANIP

21%+19.1pp

FAQ

What is Travere Therapeutics, Inc.'s return on equity?

Travere Therapeutics, Inc. (TVTX) reported return on equity of -706% in Q2 2025.

How has Travere Therapeutics, Inc.'s return on equity changed year-over-year?

Travere Therapeutics, Inc.'s return on equity decreased by 218.4% year-over-year, from -221.7% to -706%.

What is the long-term trend for Travere Therapeutics, Inc.'s return on equity?

Over 4 years (2020 to 2024), Travere Therapeutics, Inc.'s return on equity has grown at a 33.3% compound annual growth rate (CAGR), from -78.4% to -247.4%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.